Morbidity and mortality of elderly patients following cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

Morbidity and mortality of elderly patients following cytoreductive surgery and Hyperthermic... 1INTRODUCTIONCytoreductive surgery (CRS), along with hyperthermic intraperitoneal chemotherapy (HIPEC) has been gaining acceptance as the treatment of choice for selected patients with peritoneal metastases (PM) from gastrointestinal, ovarian and peritoneal origins. In a prospective study of 460 patients with PM from gastrointestinal malignancy, who underwent 501 (CRS‐HIPEC) procedures, the median survival was found to be 22.2 months with a 5‐year survival rate up to 27.8%. This exceeds the median survival of approximately 6 months for patients with PM who are treated with systemic chemotherapy or conservative management with a palliative intent.With higher life expectancy in an increasingly aging population, we can expect an increasing number of elderly patients, i.e. aged 65 and above as well. However, physicians may be less likely to consider CRS and HIPEC for elderly patients because of the presumed higher morbidity associated with age. There have been studies looking at the morbidity and mortality associated with CRS and HIPEC, but none are focused on elderly patients, with limited literature on CRS and HIPEC in the elderly population.Using prospectively collected data from a tertiary institution, we examined the outcomes of elderly patients who underwent CRS and HIPEC for PM from ovarian, colorectal and other gastrointestinal cancers, http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Asia-Pacific Journal of Clinical Oncology Wiley

Morbidity and mortality of elderly patients following cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

Loading next page...
 
/lp/wiley/morbidity-and-mortality-of-elderly-patients-following-cytoreductive-xY0i2n6rKh
Publisher
Wiley Subscription Services, Inc., A Wiley Company
Copyright
Copyright © 2018 John Wiley & Sons Australia, Ltd
ISSN
1743-7555
eISSN
1743-7563
D.O.I.
10.1111/ajco.12723
Publisher site
See Article on Publisher Site

Abstract

1INTRODUCTIONCytoreductive surgery (CRS), along with hyperthermic intraperitoneal chemotherapy (HIPEC) has been gaining acceptance as the treatment of choice for selected patients with peritoneal metastases (PM) from gastrointestinal, ovarian and peritoneal origins. In a prospective study of 460 patients with PM from gastrointestinal malignancy, who underwent 501 (CRS‐HIPEC) procedures, the median survival was found to be 22.2 months with a 5‐year survival rate up to 27.8%. This exceeds the median survival of approximately 6 months for patients with PM who are treated with systemic chemotherapy or conservative management with a palliative intent.With higher life expectancy in an increasingly aging population, we can expect an increasing number of elderly patients, i.e. aged 65 and above as well. However, physicians may be less likely to consider CRS and HIPEC for elderly patients because of the presumed higher morbidity associated with age. There have been studies looking at the morbidity and mortality associated with CRS and HIPEC, but none are focused on elderly patients, with limited literature on CRS and HIPEC in the elderly population.Using prospectively collected data from a tertiary institution, we examined the outcomes of elderly patients who underwent CRS and HIPEC for PM from ovarian, colorectal and other gastrointestinal cancers,

Journal

Asia-Pacific Journal of Clinical OncologyWiley

Published: Jan 1, 2018

Keywords: ; ;

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches

$49/month

Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

$588

$360/year

billed annually
Start Free Trial

14-day Free Trial